Breast pathology Conferences | Cancer Research Conferences | Oncologists Conferences | 2025

Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

David Ling

Stanford University USA

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Nira Ben Jonathan

University of Cincinnat USA

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Mark Priebe

Quality Star LLC USA

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Mandy Sanghera

International human rights activists UK

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Ioannis G. Papanikolaou

Obstetrician & Gynaecologist Greece

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Yihui Feng

Guangzhou University of Chinese Medicine China

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Genna Zimmel

Founder of The Deborah Zimmel Triple Negative Breast Cancer Foundation Canada

Breast pathologyLondon, Breast pathology , Breast pathology Italy, Breast pathology conference ,OncologyconferencesLondon, Cancer Research , Breast pathology meetings , Cancer Research conference , Breast pathology events , Cancer Therapy,  Breast Cancer Surgery, Cancer Genomics

Namsun Paik

Ewha Womans Cancer Center Hospital for Women South Korea

Recommended Global Pathology Webinars & Conferences

Asia Pacific & Middle East
Canada

Breast Pathology 2025

About Conference


After the success of Breast pathology 2025 in Toronto we are inviting participants across the globe to attend 22nd International Conference on Breast Pathology and Cancer Diagnosis (Breast pathology  2025) during june 19-20, 2025 in London, UK. The main theme of the conference is ‘Modern Innovation to Breast Cancer Research’. The relative novel nature of the conference and its relevance to the current Breast cancer makes this summit an event to look forward for all the individuals of the Breast Pathology Community.

Details of Breast Pathology 2023 in Montreal, Canada

Conference Name

Place

Date

Breast Pathology 2025

London, Uk

june 19-20, 2025

About Breast Pathology..!!

The knowledge and understanding of pathology is significant in modern medical diagnosis and research as it involves treatment of the essential nature of certain ailments, especially the changes that directly affect the body tissues and organs.

Cancer or Carcinoma is a group of diseases involving abnormal cellular growth and division. When cells start proliferating rapidly in an uncontrolled manner in the breast, it is called Breast Cancer. Signs of breast cancer may include a lump in the breast, a change in breast shapedimpling of the skin fluid coming from the nipples or a newly inverted nipple. Breast Cancer starts when cells in the breast begin to proliferate tremendously. Breast Cancer occurs almost entirely in women, but men can also catch it. Breast Cancer can start from different parts of the breast.

Typically, treatment plans are based on the type of breast cancer, its stage, etc. It basically depends upon other factors as well such as overall health and personal preferences. Drugs used in breast cancer treatment are considered as Systemic Therapies as they can reach cancer cells almost anywhere in the body. Common systemic treatments include: Chemotherapy for Breast Cancer, Hormone Therapy for Breast CancerTargeted therapy for Breast Cancer.

Audience:

PathologistResearchersGynaecologistsOncologistRadiation OncologistPalliative MedicinePrimary Care ProvidersPlastic SurgeonsSurgeonsWomen's Healthcare professorsepidemiologistsBreast cancer Nurses, Patients, Councillors & who all are the part of Breast Pathology; to pool the knowledge on current trends of Breast pathology diagnosis and Treatment . Breast Pathology 2025 came up with a theme "Modern Innovation to Breast Cancer Research".

Conference Highlights

  • Breast Cancer
  • Cancer Genetics
  • Types of Breast Cancer
  • Cancer Research
  • Breast Cancer Screening
  • Breast Pathology Diagnosis
  • Cancer Genomics
  • Cancer Therapy
  • Breast Cancer Monitoring
  • Cancer Diagnosis
  • Breast Pathology Benign and Malignant Tumors
  • Breast Pathology Treatment
  • Treating HER2 Breast Cancer with Targeted Therapies
  • Breast Pathology Surgery
  • Breast Pathology and Pregnancy
  • Latest Advances in the Management of Breast Cancer
  • Innovative Therapeutic Approaches in Breast Cancer Therapy
  • Newest clinical trials and their potential impact on New Treatments
  • Breast Pathology and Prevention

What is Breast Cancer?

Breast cancer is a disease that forms cancer in the cells of the breast, where the proliferation of abnormal cells takes place that destroys body tissues. The tumor formed can be felt as a lump or can be seen by X-ray.

Malignant tumor cells can penetrate different parts of the body; destroy adjacent tissues and forms new tumors. The tumor can be diagnosed by special tests like mammography, X-ray etc. and was studied under the microscope by a specialist known as " Pathologist ". Each report diagnosed by the pathologist will be sent to the doctor for final confirmation. Breast Pathology and Diagnosis 2023 conference provide complete knowledge about symptoms, causes, risks, and preventive measures.

Target Audience

· Women's Healthcare professors
· Researchers, nurses
· Cancer center Managers
· Vice Presidents or Directors
· Brand Manufacturers or Marketers of screening instrumental Products
· Professors, Directors or Co-directors
· Medical Oncologists, Surgical Oncologists
· Teachers seeking educational material
· Radiation Oncologists
· Surgeons, Gynaecologists
· Pathologists
· Epidemiologists
· Breast cancer Nurses & Trainees in breast pathology
· Medical staff & Medical Journalists
· Researchers and Students from Academia in the study of Women's health filed.
· Pharmaceutical researchers
· Clinical organizations
· Educational institutes
· Other healthcare professionals interested in the latest advances and techniques in the field

 

Welcome Note

Dear Esteemed Guests and Participants,

On behalf of the organizing committee, it is my great pleasure to welcome you to the International Conference on Breast Pathology and Cancer Diagnosis, taking place on June 19-20, 2025. We are excited to bring together leading experts, researchers, and practitioners from around the globe to share insights and advancements in this vital field.

Breast cancer remains a significant health challenge worldwide, and this conference serves as a platform for collaboration and knowledge exchange. Over the next two days, we will delve into a range of topics, including cutting-edge research, innovative diagnostic technologies, and best practices in pathology.

We encourage you to engage actively in the sessions, connect with your peers, and share your experiences. Together, we can drive forward advancements that will improve patient outcomes and enhance our understanding of breast pathology.

Thank you for joining us for this important event. We look forward to an inspiring and fruitful conference!

Warm regards,

Octavian Bucur, MD PHD

Conference co-chair

New generation pathology group

Co-Editor in chief of discoveries journal

 

Session and Tracks

Session 1: Breast Cancer Pathology

There are trillions of cells in the body. These cells have controlled cell cycle that controls their development, development, division, and demise. When they attain adulthood, the cells replicate to replace exhausted cells and to repair wounds. Cancer initiate when cells in a part of the body start to grow out of control. All types of cancer, irrespective of their origin, occur due to this uncontrollable growth of cells that leads to the formation of tumours and lesions. Cancer that develops from breast cells is known as Breast Cancer. Tumour formed by these cells can be seen on an x-ray or felt as a lump. When tumour cells grow into surrounding tissues or spread to distant areas of the body it become malignant. Breast cancer mainly occurs in women but man can also develop breast cancer, too. Breast cancer can develop from different parts of the breast. But most of the time the ducts that carry milk to nipple act as site for breast cancer. It may also start from the glands that make breast milk. Sarcomas and lymphomas are not really considered as breast cancer but they can also start from other tissues in the breast. Lump in the breast are not cancer but they are benign means they will not spread out, they are abnormal growths. But they can increase the risk for woman of getting breast cancer. When breast cancer cells enter blood or lymph system can spread the cancer and carry to the other part of the body. If the breast cancerous cells enter the lymph nodes it increases the chance of getting to spread to the other part of the body.

Session 2: Breast Diseases

There are several categories of breast diseases which may cause infections, cysts and lumps with or without pain. Some of the breast diseases are benign (harmless) and some are malignant (which can spread). Most common breast diseases are mastitis (a bacterial infection), cysts, benign lumps and cancer. Women mostly are affected by the breast diseases where they are encouraged to start breast self-examination early in the life and to have regular mammography, if found suspicious they are generally offered with a combination of ultrasound and needle biopsy to work out the cause. Men are affected by breast diseases too, although not as often.

Session 3: Breast Cancer Grading and Staging

Staging and grading are ways in which healthcare professionals describe the size of your breast cancer, whether and how far it has spread, and how fast it may grow. Grading is Assess by evaluating acinar formation, nuclear size/pleomorphism and mitotic activity. An attempt should be made to grade the pre-operative core biopsy as there is acceptable concordance with excision grade.

Grading:

Grade 1 – the cancer cells look small and uniform like normal cells, and are usually slow-growing compared to other grades of breast cancer

Grade 2 – the cancer cells are slightly bigger than normal cells, varying in shape and are growing faster than normal cells

Grade 3 – the cancer cells look different to normal cells, and are usually faster-growing than normal cells

Staging: Staging is used to assess the size of a tumour, whether it has spread and how far it has spread. Understanding the stage of the cancer helps doctors to predict the likely outcome and design a treatment plan for individual patients.

Stage 1: Usually means that a cancer is relatively small and contained within the breast.

Stage 2 usually means the cancer has not started to spread into surrounding tissue but the tumour is larger than in Stage 1. Sometimes Stage 2 means that cancer cells have spread into lymph nodes close to the tumour.

Stage 3 usually means the cancer is larger. It may have started to spread into surrounding tissues and there are cancer cells in the lymph nodes in the area.

Stage 4 means the cancer has spread from where it started to another body organ. This is also called secondary or metastatic cancer.

Session 4: Recurrent Breast Cancer

The cancer does return after treatment for early-stage disease, it is called recurrent cancer. When breast cancer recurs, it may come back in the following parts of the body, same place as the original cancer, chest wall, lymph node, bones, lungs, liver and brain.

Session 5: Screening, Monitoring and Diagnosis

Breast Cancer can be detected through screening tests. Screening earlier can improve the chances of survival. Clinical breast exam, Biopsy and mammography are breast cancer screening tests.  At higher risk of breast cancer breast MRI can also be used for some women. Powerful magnetic field and radio waves are used during Magnetic resonance imaging (MRI), which produces detailed images of structures within the breast. If breast cancer gets detected either by screening tests or from symptoms diagnostic tests are given to the woman who is suspected of having breast cancer.

Diagnostic tests includes Mammogram (X-ray of breast), Breast ultrasound (uses sound waves to produce pictures of structures), Removing a sample of breast cells for testing (biopsy), Breast magnetic resonance imaging (MRI).These diagnostic tests confirm the presence or absence of breast cancer and give more information about breast cancer like whether it has travelled outside the breast or not. Many tests are used to monitor how well therapies are working after the diagnosis of breast cancer.

Session 6: Breast Pathology Treatment and Drugs

Breast cancer treatment team mainly includes Breast surgeon, surgical oncologist, radiation oncologist, medical oncologist, plastic surgeon. It also includes a variety of other health care professionals, including physician assistants,  oncology nurses, social workers, pharmacists, counsellors, nutritionists, and others. The biology and behaviour of a breast cancer affects the treatment plan. Treatment options and recommendations are very personalized and depend on several factors, including: stage of tumour, tumour subtypes, genomic maker, patient age, and patient menopausal status, mutations in inherited breast cancer genes, such as BRCA1 or BRCA2. For both DCIS and early-stage invasive breast cancer, doctors generally perform surgery to remove the tumour. For larger cancers, or those that are growing more quickly, doctors may recommend systemic treatment with chemotherapy or hormonal therapy before surgery, called neoadjuvant therapy.

Session 7: Breast Cancer Surgery

Breast surgery may be done for many causes, depending on the condition of the patient. Most women with breast cancer have some type of surgery as part of their treatment. Surgery may be done to remove the maximum cancer cells as possible (breast-conserving surgery or mastectomy) and to find out whether the cancer has spread to the lymph nodes under the arm (sentinel lymph node biopsy or axillary lymph node dissection) and/or restore the breast’s shape after the cancer is removed (breast reconstruction) and to relieve symptoms of advanced cancer.

Session 8: Breast Cancer Pathology in Pregnancy

Breast cancer is found in about 1 in every 3,000 pregnant women. Breast cancer is the most common type of cancer found during pregnancy, while breastfeeding, or within the first year of delivery. You may hear this called gestational breast cancer or pregnancy-associated breast cancer (PABC). Sometimes due to hormonal changes in pregnancy, cancer may spread to lymph nodes. Pregnancy and breast feeding can also make breast tissue denser. Breast cancer may occur during the pregnancy and after the birth of child although the chances are less. Woman who is previously diagnosed with breast cancer and is now pregnant should take advice of consultant. Pregnancy is not a reason of breast cancer, but chances can be there in the women who are diagnosed from breast cancer. Treatment of breast cancer during the pregnancy depends upon size of tumour. Decisions should there between the consultant, surgeon and oncologist. And family support is also required at the same time.

Session 9: Latest Advances and Innovative Therapeutic Approaches

Breast Pathology  will be a chief interdisciplinary stage for the introduction of new advances and research results in the fields of Breast Cancer and Cancer Science. The meeting will unite driving scholastic researchers, analysts and researchers in the space of enthusiasm from around the globe. Topis of interest for submission include, but are not limited to:

Session 10: Male Breast Cancer

Breast cancer in men is a rare disease. Less than 1% of all breast cancers occur in men. Man, and women, girls and boys all have breast tissues. The various hormones in girls' and women's bodies stimulate the breast tissue to grow into full breasts. Boys' and men's bodies normally don't make much of the breast-stimulating hormones. As a result, their breast tissue usually stays flat and small. But sometimes men can develop real breast gland tissue because they take certain medicines or have abnormal hormone levels. In 2018, about 2,550 men are expected to be diagnosed with the disease. For men, the lifetime risk of being diagnosed with breast cancer is about 1 in 1,000.

Session 11. Breast Cancer Prevention

Women may reduce their risk of breast cancer by maintaining a healthy weight, drinking less alcohol, being physically active and breastfeeding their children. Avoiding risk factors and increasing protective factors may help prevent cancer. The following are risk factors for breast cancer: Older age, A personal history of breast cancer or benign (no cancer) breast disease, A family history of breast cancer, Inherited gene changes, Dense breasts, Exposure of breast tissue to oestrogen, made in the body, Taking hormone, therapy for symptoms of menopause, Radiation therapy to the breast or chest, Obesity, Drinking alcohol.

Session 12: Breast Cancer and Genetics

The two most common genetic risk factors for breast cancer are the BRCA1 BRCA2 genes. Approximately 5% of all breast cancers are caused by a recognised specific genetic predisposition due to germ line mutations of one of two different genes: BRCA1 located on Chromosome 17q, BRCA2 located on Chromosome 13q. BRCA1 mutations also predispose to carcinoma of the ovary and possibly carcinoma of the Fallopian tube. The risk of developing breast cancer among carriers is around 55% by age 70. BRCA2: The product of BRCA2 is involved in controlling gene function and DNA repair. Gene function involves in transcriptional activation and completion of cell division by cytokinesis.  Majority of BRCA2-associated tumours are invasive ductal, no special-type tumours.

 

Session 13: Breast Pathology and Immunohistochemistry

Immunohistochemistry is a special staining process performed on fresh or frozen breast cancer tissue removed during biopsy. IHC is used to show whether or not the cancer cells have HER2 receptors and/or hormone receptors on their surface. This information plays a critical role in treatment planning. Immunohistochemistry (IHC) is used to characterize intracellular proteins or various cell surfaces in all tissues. Individual markers, or more often panels of various marker proteins, can be used to characterize various tumor subtypes, confirm tissue of origin, distinguish metastatic from primary tumor, and provide additional information which may be important for prognosis, predicting response to therapy, or evaluating residual tumor post-treatment. There is a growing list of available antibodies, which contribute to the broader utility of immunohistochemistry for solving diagnostic problems or for determining prognosis and response to therapy in breast pathology.

Session 14: Case study and Case Reports

In medicine, a case report contains detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case report usually describes an unusual or novel occurrence. Case reports are an unexpected association between diseases or symptoms. It may results in finding the shed new light on the possible pathogenesis of a disease or an adverse effect. It may contour Unique or rare features of a disease, unique therapeutic approaches.

Session 15: Special Types of Breast Cancer

20% of breast carcinomas are of special type and the majority of these are lobular carcinomas. Tubular and mucinous carcinomas occur next most frequently and thereafter the remaining special types are seen infrequently. Special types of carcinoma should be distinguished from mixed carcinomas where the special type areas occupy between 50 and 90% of the tumour area with the remaining area being usually of no special type.

Session 16: Women’s Health and Fitness

Breast health begins with a sense of what's normal for your breasts (breast awareness). To promote breast health, consider doing regular breast self-exams. For many women, breast health includes concerns about breast lumps, breast pain or nipple discharge. It's also important to understand common screening and diagnostic tests for breast health, such as clinical breast exams, mammograms and breast ultrasounds.

Session 17: Nursing and Palliative care rehabilitation

The treatment and the cancer itself may affect the physical functioning and energy of the body. Life after breast cancer treatment gets changed like returning to some familiar things and new choices to make. After the last steps of treatment like radiation or diagnostic procedure is not the end of fighting against breast cancer. Physical energy and functioning can also be getting affected after the breast cancer treatment. Level of oestrogen may also get lowered after the treatment which leads to the decrease in bone density. Bone density can be increased as well recurrence of breast cancer can be prevented with the help of exercise. During oncology rehabilitation physical functioning as well as sense of well-being can be improved.

Oncology nurses are critical participants in the delivery of palliative care. It is the position of oncology nurse that primary nursing should begin at the time of diagnosis and continue throughout bereavement. Physical, psychological, social, cultural, and spiritual assessments are key components to the development of a comprehensive care plan for each patient. Oncology nurses must possess knowledge and skills in certain domains to deliver safe, quality palliative care including structure and processes of care, physical aspects of care, psychological care, and social aspects for care, cultural aspects of care, care of the imminently dying patient, ethical and legal aspects of care and, spiritual, religious, and existential aspects of care of a cancer patient. Oncology nurses have a responsibility to engage the public and provide fact-based information about care of people with advanced serious illness to encourage advance care planning and informed choices based on the needs and values of individuals.

Session 18: Breast Cancer: Challenges, Breakthroughs

Breast cancer is the second most common cancer diagnosed after lung cancer and is the main cause of cancer demise in women. The heterogeneity of breast cancer such as ductal carcinoma in situ, triple negative breast cancer, HER2 negative among the women makes it difficult for the doctors to provide ideal medications for the cure. The major treatment methods are chemotherapy, radiation therapy, targeted drug therapy, oncoplastic surgery etc. Recent oncology research lead to the developments in neoadjuvant  therapies, have also been benefited in treatment of breast cancer. Complete cure through Ayurveda was another major breakthrough in breast cancer treatment.

Session 19: Breast Implants

There are three general types of breast implant devices, defined by their filler material saline solution silicone, silicone gel and composite filler. The saline implant has an elastomer silicones shell filled with sterile saline  solution during surgery the silicone implant has an elastomer silicone shell pre-filled with viscous silicone gel and the alternative composition implant featured miscellaneous fillers such as soy oil, polypropylene string etc.

 

Market Analysis

Approximately 13% (about one in eight) of U.S. women will develop invasive breast cancer in the course of their life. In recent years, incidence rates have increased slightly by 0.5% per year. Breast cancer is still one of the leading causes of cancer-related death in U.S. women, second only to lung cancer.  
Breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers. Each year, about 30% of all newly diagnosed cancers in women are breast cancer. In 2024, approximately 310,720 women and 2,800 men will be diagnosed with invasive breast cancer. About 66% of breast cancer cases are diagnosed at a localized stage — before cancer has spread outside of the breast — when it is easiest to treat. There are currently more than four million women with a history of breast cancer in the United States. This includes women currently being treated and women who have finished treatment. In the United States, less than 1% of all breast cancers occur in men.  

HISTORICAL INCIDENCE RATES :
After increasing for the previous two decades, breast cancer incidence rates in the United States began decreasing in 2000. One theory is that this decrease was partially due to the reduced use of hormone replacement therapy (HRT) by women after the results of a large study called the Women’s Health Initiative were published in 2002. These results suggested a connection between HRT and increased breast cancer risk

.

Diagnostic centres and medical laboratories are poised for rapid growth in the breast cancer diagnostics market. These facilities play a crucial role in diagnosing breast cancer through various biopsy techniques such as fine-needle aspiration, core needle biopsy, MRI-guided biopsy, or surgical biopsy. Specialists analyse tumour samples and genetic profiles in laboratories. Hormone receptor and HER2/neu tests are common lab procedures. These centres facilitate accurate diagnosis and personalized treatment planning for patients, driving growth in the market.

GENETICS:

About 5% to 10% of breast cancers can be linked to known gene mutations inherited from one’s mother or father. Mutations in the BRCA1 and BRCA2 genes are the most common.

 

About 85% of breast cancers occur in women who have no family history of breast cancer. These occur due to genetic mutations that happen as a result of the aging process and life in general, rather than inherited mutations. On average, women with a BRCA1 mutation have up to a 72% lifetime risk of developing breast cancer. Women with a BRCA2 mutation have up to a 69% risk. Breast cancer that is positive for the BRCA1 or BRCA2 mutations tends to develop more often in younger women. An increased ovarian cancer risk is also associated with these genetic mutations.  In men, BRCA2 mutations are associated with a lifetime breast cancer risk of about 6.8%; BRCA1 mutations are a less frequent cause.


Breast Cancer Diagnostics Market Size in the U.S. 2023 to 2032

The U.S. Breast Cancer Diagnostics market size was valued at USD 1.51 billion in 2023 and is anticipated to reach around USD 3 billion by 2033, growing at a CAGR of 7.1% from 2024 to 2033.

North America dominated the market with a revenue share of 46.00% in terms of revenue in 2023, According to U.S. Cancer Statistics, breast cancer is the most frequently diagnosed cancer among American women, excluding nonmelanoma skin cancers. It ranks as the second leading cause of cancer-related deaths among women overall, with lung cancer being the only one surpassing it. However, among Black and Hispanic women, breast cancer stands as the primary cause of cancer-related mortality.

 

Benefits of Participation

Advantages of Participating at our conference:

  • As an add on advantage the Speaker & Abstract pages created in Google on your profile under your name would get worldwide visibility.
  • Our robust online publicity attracts 20000+ users and 60000+ views to our Library of Abstracts which brings worldwide exposure to the researchers and speakers participate in our conferences.
  • All the conference participants can earn up to 16-18 CME Credits by participating at our Breast pathology 2025  Conference scheduled at Montreal, Canada.
  • To attain professional development we offer our participants a chance to earn up to 21 CPD Credits authorized by CPD Standards Office, UK by participating at our Breast pathology 2025.
  •  All the conference participants will be awarded with IOCM Certification.
  •  All the conference participants will have an unique opportunity to participate at One on One Meeting with Eminent Speakers.
  •  A Unique opportunity to hear what the global researchers are talking about at our Keynote sessions by world’s most eminent researchers in the field of  Breast pathology 2025.
  • Top Industries Representation of Industrial Leaders, where you get a great opportunity to meet and discuss with the Industrial Leaders in person.
  • Thought provoking Symposia’s.
  •  Workshops on Carrier Development.
  •  Preconference workshops in all major countries.
  •  Nominations for Best Poster Award.
  •  Outstanding Young Researcher Award.
  •  Group registration benefits.

Benefits of Participation | Speaker

  • Explore the best in Cutting edge Research.
  • Worldwide acknowledgment of Researcher’s profile.
  • Obtain professional development credits.
  • Your presence and talk will be recorded and hosted on YouTube and Video which in turn will gain potential value to your research profile.
  • Make Lasting connections at Networking and Social Events.
  • We provide unique convergence of Networking, Learning and Fun into a single package.
  • An opportunity to give One page advertisement in abstract book and flyers distribution which eventually gets 1 Million views and add great value to your research profile.
  • Learn beyond your field of interest, a change to know more about the new topics and research apart from your core subject.

Benefit of Participation | Sponsor

  • Worlds No1 Platform to show case  Breast pathology 2023 Products.
  • Exposure to the international atmosphere will increase the odds of getting new business.
  • Opportunity to showcase the new technology, new products of your company, and/or the service your industry to a broad international audience.
  • Attain with an exceptional format in showcasing the products and services and to gain the potential clients for the future business prospects.
  • Our Breast pathology 2025Conference in the one and only location to reach the top customers.
  • Make new connections and fostering potential partnerships.
  • Increase your business by lead generation through our conference participants.
  • Build a successful business takes a lot of time, effort and drive, so it’s always good to have a network of colleagues and associates to draw energy from people who share a similar drive and objective.
  • Flip side of learning new things is relearning classic techniques. Breast pathology 2025 conferences create opportunities for greater focus and reflection that could help you take your business to the next level.
  • Benchmarking key strategies for business and moving it forward.
  • Get answers to your business questions and challenges from credible individuals at our conference.
  • Exposure and Networking Opportunity with the various top decision makers of the respective organizations, will eventually grow your business in Global market.
  • Get to know more about your competitors are first-hand, learn more about their businesses, and discover their strengths and weaknesses, all of which can add to your business’s competitive edge.
  • Encounter new vendors and suppliers for your business.
  • Real Benefits in New business - Many Organizations make deals and sign contracts at our Breast pathology 2025 .
  • We offer you the Website visibility to more than 35K visitors in less than 6 months.
  • Promotional logo of your organisation at our conference banner, website and other proceedings, branding and marketing material.
  • Hosting session slots, poster awards, recognition in opening ceremony and complimentary registrations, exhibition/workshop booth, low-budget options.

Benefit of Association for Collaborators

  • No one in the world have this huge visitors towards Breast pathology 2025, these is the best platform to show case your society.
  • Create long-lasting relationships with the peers.
  • Promotional content and Logo of your Association at our conference banner, website and other proceedings, branding and marketing material will increase your subscribers/Members number by 20 %.
  • Our Website visibility to your Organization page can give a great impact for your association in the Global Market.
  • Your representatives can network with key conference delegates to update their knowledge and understanding of your organization and services.
  •  Details will be added to the conference press release where the details will be shared to < 100000 outlets.
  •  Details will be incorporated in all conference promotional materials which will be distributed to Hospitals, Universities, Society and Researchers.

Benefits of Participation | Delegate

  • Helps to meet Experts & Influencers Face to Face.
  • Opportunities to meet researchers and experts of same field and share new ideas.
  • Can help to know New Tips & Tactics.
  • Professional Development – Elevate your knowledge and Skills.
  • Conference attendance inspires, rejuvenates, and energizes delegates.
  • Your participation at our conference will be helpful for a new approach and ideology that can be utilized for the extending the outcome of Companies or Industries.
  • Enjoy the alluring city environment where the conference is being held.
  • Raise your profile by being well-known

 

Visa Application Process

Visa Application Documents You should only apply for business visas to attend and attend conferences. Contact your nearest Montreal, Canada Travel Agency/Visa Information Center/Embassy for the correct application form.

All visas for the visit to Montreal, Canada are processed by the respective embassy authorities in the correct way only after the presentation of the corresponding documents.

If no documents are provided or if the guidelines are not followed, the competent authorities hold the right to reject/cancel the visas.

The minimum documents that may be required when applying for the visa from / Montreal, Canada include:

  • Official Letter of Invitation
  • Letter of Acceptance/Approval for abstracts (if you are a speaker)
  • Proof of payment receipt for registration
  • Hotel Booking Confirmation Letter for accommodation issued on conference letterhead

 

To Collaborate Scientific Professionals around the World

Conference Date June 19-20, 2025

Speaker Opportunity

Supported By

Cancer Science & Therapy Journal of Clinical & Experimental Pathology Breast Cancer: Current Research

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • Biomarkers
  • Breast Cancer
  • Case Studies
  • Clinical Trials
  • Community Outreach
  • Continuing Education
  • Cytopathology
  • Diagnosis
  • Early Detection
  • Education
  • Ethical Considerations
  • Expert Panels
  • Funding Opportunities
  • Future Directions
  • Genetic Testing
  • Genomics
  • Global Health
  • Guidelines
  • Health Disparities
  • Histopathology
  • Immunohistochemistry
  • Innovations
  • Interdisciplinary Research
  • Liquid Biopsy
  • Molecular Diagnostics
  • Multidisciplinary Approach
  • Networking
  • Pathology
  • Patient Advocacy
  • Patient Outcomes
  • Personalized Medicine
  • Prognosis
  • Public Awareness
  • Quality Assurance
  • Radiogenomics
  • Radiology
  • Recurrence
  • Regulatory Issues
  • Research Collaborations
  • Risk Assessment
  • Risk Factors
  • Screening
  • Staging
  • Standardization
  • Survival Rates
  • Technology
  • Therapeutic Targets
  • Treatment Strategies
  • Tumor Microenvironment
  • Workshops